TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12465429
Drug: Tacrolimus +
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus + MMF + Steroids (Tac/MMF/S)
Study: 12465429
Drug: Tacrolimus +
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus + Azathioprine + Steroids (Tac/Aza/S)
Study: 10502909
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion (1 mg.kg‐1.hr‐1)
Study: 8746887
Drug: Difference in
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Difference in median survival times between treatment groups
Study: 1646250
Drug: Intranasal human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal human calcitonin (hCT) plus sodium glycocholate (SGC)
Study: 1646250
Drug: Intramuscular human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular human calcitonin (hCT) 100 U on alternate days
Study: 1646250
Drug: Intranasal human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal human calcitonin (hCT) 100 U/day
Study: 1646250
Drug: Intramuscular human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular human calcitonin (hCT) 100 U/day
Study: 30633057
Drug: Pulsed flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed flow oxygen (2 to 10 L/min for volunteers; 1 to 5 L/min for patients)
Study: 30633057
Drug: Continuous flow
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous flow oxygen (2 to 10 L/min for volunteers; 1 to 5 L/min for patients)
Study: 30633057
Drug: Pulsed flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed flow oxygen (1 to 5 L/min for patients)
Study: 30272234
Drug: Oral E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral E2 with/without cyclic vaginal progesterone
Study: 27397522
Drug: Pregabalin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (50 mg every other day)
Study: 27397522
Drug: Doxepin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxepin (10 mg per day)
Study: 26431666
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine combined with doxycycline
Study: 23537882
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise programme (12-week, twice-weekly)
Study: 11822612
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medical acupuncture treatment using an average of 12-13 needles per treatment, with more than 85 different acupoints utilized.
Study: 11822612
Drug: Adjunctive treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive treatments including heat (36%-67%) and cupping (16%-21%).
Study: 7877115
Drug: Adrenomedullary system
Normalized name: Adrenomedullin
DrugBank: Adrenomedullin (DB19102)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenomedullary system activation measured by norepinephrine (NE) and normetanephrine excretion
Study: 31696972
Drug: Low-intensity cognitive
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity cognitive behavioural therapy (LICBT)
Study: 31696972
Drug: Pre-treatment variables
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment variables (unemployment, suicide risk, neglect, medication, previous or concurrent treatments, longer duration of difficulties, comorbidities)
Study: 29380013
Drug: Denosumab 60
Normalized name: denosumab 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 60 mg Q6M for 10 years
Study: 29380013
Drug: Denosumab 60
Normalized name: denosumab 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 60 mg Q6M for 7 years
Study: 28664242
Drug: Rituximab (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (375 mg/m2 once weekly for 4 weeks)
Study: 24902673
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy (63 patients, 12 sessions of 60 min/week for 3 months)
Study: 23435876
Drug: 1,25-D3 (calcitriol)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,25-D3 (calcitriol) at 60 mcg/m2 every 21 days with cisplatin 75 mg/m2 and docetaxel 75 mg/m2
Study: 23435876
Drug: CYP24A1 SNP
Normalized name: SNP-ACTH (1-39)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP24A1 SNP rs2762939 (C > G)
Study: 18458207
Drug: Eszopiclone (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eszopiclone (3 mg nightly for 8 weeks) + Escitalopram (10 mg for 10 weeks)
Study: 14990264
Drug: Glycyl-glutamine-supplemented parenteral
Normalized name: glycyl-isolysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycyl-glutamine-supplemented parenteral nutrition (20 g of glutamine)
Study: 14990264
Drug: Standard glutamine-free
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard glutamine-free parenteral nutrition
Study: 14990264
Drug: Glycyl-glutamine-supplemented parenteral
Normalized name: glycyl-isolysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycyl-glutamine-supplemented parenteral nutrition
Study: 11380464
Drug: 7‐3 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7‐3 plus high‐dose cytarabine (HIDAC‐3‐7) chemotherapy
Study: 11380464
Drug: 7‐3 chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7‐3 chemotherapy (standard dose cytarabine and daunorubicin)
Study: 11380464
Drug: 7‐3 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7‐3 plus etoposide (7‐3‐7) chemotherapy
Study: 9052890
Drug: Sustained-release verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release verapamil (calcium channel blocker)
Study: 7639352
Drug: BN 52021
Normalized name: MVA-BN
DrugBank: Modified vaccinia ankara (DB15483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BN 52021 (120 mg)
Study: 31451130
Drug: Intranasal ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal ketamine (4 mg/kg)
Study: 10323118
Drug: Oral chloral
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral chloral hydrate (50 mg/kg)
Study: 27568351
Drug: High molecular
Normalized name: dextran, high molecular weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: High molecular weight Sodium Hyaluronate (3%) plus saline solution (3 mL sodium chloride-NaCl-0.9%) using a nebulizer ampoule for nasal douche, administered twice a day for 30 days.
Study: 27568351
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (6 mL sodium chloride-NaCl-0.9%) using a nebulizer ampoule for nasal douche, administered twice a day for 30 days.
Study: 27568351
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received Levofloxacin (500 mg for 10 days) and Prednisone (50 mg for 8 days, 25 mg for 4 days, and 12.5 mg for 4 days).
Study: 26258474
Drug: Intermittent Screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent Screening and Treatment with artemether-lumefantrine (ISTp-AL)
Study: 26258474
Drug: Intermittent Preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent Preventive Treatment with sulfadoxine-pyrimethamine (IPTp-SP)
Study: 21781652
Drug: Hydralazine 182
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine 182 mg/day for fast acetylators
Study: 21781652
Drug: Hydralazine 83
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine 83 mg/day for slow acetylators
Study: 21781652
Drug: Hydralazine 182
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine 182 mg/day for cancer patients (fast acetylators)
Study: 21781652
Drug: Hydralazine 83
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine 83 mg/day for cancer patients (slow acetylators)
Study: 19349894
Drug: Oral arginine
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral arginine supplementation (36.2 g of l-arginine-HCl)
Study: 19349894
Drug: Placebo (51.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (51.2 g alanine)
Study: 12009347
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg/day) for 6 months
Study: 9538966
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro administered 10 min preprandial
Study: 9538966
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro administered 20 min postprandial
Study: 9538966
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro administered preprandially with high-carbohydrate meals
Study: 9538966
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro administered preprandially with solid high-fat meal
Study: 7480971
Drug: Taurine administered
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taurine administered intravenously before and during anesthesia
Study: 2964388
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion 5-fluorouracil (5-FU) or 5-fluorouracil-deoxyribose as single agents or in combination with other drugs
Study: 1535215
Drug: Topical benzoyl
Normalized name: benzoyl peroxide Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical benzoyl peroxide
Study: 29200982
Drug: Native whey
Normalized name: whey protein hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Native whey protein (2×20 g)
Study: 29200982
Drug: WPC‐80 (2×20
Approvals — FDA: no, EMA: no, PMDA: no
Description: WPC‐80 (2×20 g)
Study: 23059756
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of chondroitin 4&6 sulfate 1200 mg (CS 1200)
Study: 23059756
Drug: Three daily
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three daily capsules of chondroitin 4&6 sulfate 400 mg (CS 3*400)
Study: 17682008
Drug: GONB and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: GONB and TPIs using lidocaine 2% and bupivacaine 0.5% + triamcinolone 40 mg
Study: 14587650
Drug: Spironolactone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (25 mg)
Study: 14587650
Drug: Metoprolol (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (12.5 mg)
Study: 8971296
Drug: Oral erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral erythromycin (160 mg/h)
Study: 8004841
Drug: Bisoprolol 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol 20 mg
Study: 27473400
Drug: Monthly payment
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly payment disbursement
Study: 27473400
Drug: Semi-monthly payment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semi-monthly payment disbursement
Study: 27473400
Drug: All intervention
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All intervention arms (monthly and semi-monthly)
Study: 20495474
Drug: On-site, nurse-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-site, nurse-administered intervention
Study: 9106905
Drug: m-CPP (0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: m-CPP (0.08 mg/kg)
Study: 6591741
Drug: metrizoate 200
Normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: metrizoate 200 mg I/ml
Study: 6591741
Drug: iohexol 240
Normalized name: iohexol 240 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: iohexol 240 mg I/ml and iohexol 300 mg I/ml
Study: 22198776
Drug: Diclofenac 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 100 mg rectally 30 to 60 minutes before ERCP plus somatostatin 0.25 mg/h for 6 hours
Study: 22198776
Drug: Placebo suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo suppository and saline solution
Study: 21034824
Drug: Recombinant adenovirus
Normalized name: Adenovirus/PNP
DrugBank: Adenovirus/PNP (DB17175)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant adenovirus serotype 5 (rAd5) vaccine encoding the envelope glycoprotein (GP) from the Zaire and Sudan Ebola virus species, administered at 2×10(9) viral particles (n=12)
Study: 21034824
Drug: Recombinant adenovirus
Normalized name: Adenovirus/PNP
DrugBank: Adenovirus/PNP (DB17175)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant adenovirus serotype 5 (rAd5) vaccine encoding the envelope glycoprotein (GP) from the Zaire and Sudan Ebola virus species, administered at 2×10(10) viral particles (n=11)
Study: 9661803
Drug: Temocapril, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temocapril, 2 to 4 mg once daily for 12 months
Study: 11131271
Drug: Diuretic (trichlormethiazide)
Normalized name: Trichlormethiazide
DrugBank: Trichlormethiazide (DB01021)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diuretic (trichlormethiazide) continued for an additional 12 months
Study: 8825539
Drug: Local infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infiltration with lidocaine 1% with adrenaline 1:200,000, 0.4 ml.kg‐1 (n = 21)
Study: 8825539
Drug: Nerve blockade
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve blockade with bupivacaine 0.5%, 0.4 ml.kg‐1 (n = 22)
Study: 2990260
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received the same drugs (droperidol, flunitrazepam, pancuronium, nitrous oxide with oxygen)
Study: 29063860
Drug: Voxilaprevir (VOX)
DrugBank: Voxilaprevir (DB12026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Voxilaprevir (VOX) 100 mg
Study: 25223172
Drug: Kuntai Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kuntai Capsule (KC)
Study: 17679728
Drug: Anastrozole 1
Normalized name: anastrozole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole 1 mg daily for 16 weeks + gefitinib 250 mg/d orally for 16 weeks
Study: 17679728
Drug: Anastrozole 1
Normalized name: anastrozole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole 1 mg daily for 16 weeks
Study: 10190536
Drug: Alternate-day simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alternate-day simvastatin and fenofibrate therapy
Study: 10190536
Drug: Standard daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard daily combination of simvastatin and fenofibrate
Study: 7799040
Drug: Very low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Very low-dose warfarin (VLDW)
Study: 28060040
Drug: Cysticidal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cysticidal therapy
Study: 25962515
Drug: OPTIMAL (occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPTIMAL (occupational therapy led self-management support programme)
Study: 22185865
Drug: Low-dose multidetector
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose multidetector computed tomography (CT) screening
Study: 15310780
Drug: Control (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (placebo or no therapy)
Study: 11497229
Drug: New cytotoxic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New cytotoxic drugs (vinorelbine, paclitaxel, docetaxel, gemcitabine, irinotecan)
Study: 11497229
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cisplatin and newer drugs
Study: 11497229
Drug: Docetaxel and
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel and other newer drugs
Study: 11497229
Drug: Newer drug
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Newer drug combinations
Study: 9462204
Drug: LAC (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAC (30 mg of lansoprazole twice daily + 1 g of amoxycillin twice daily + 400 mg of metronidazole twice daily)
Study: 9462204
Drug: LAM (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAM (30 mg of lansoprazole twice daily + 1 g of amoxycillin twice daily + 250 mg of clarithromycin twice daily)
Study: 9462204
Drug: LCM (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCM (30 mg of lansoprazole twice daily + 400 mg of metronidazole twice daily + 250 mg of clarithromycin twice daily)
Study: 9462204
Drug: OAM (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAM (20 mg of omeprazole twice daily + 1 g of amoxycillin twice daily + 400 mg of metronidazole twice daily)
Study: 22151836
Drug: Mealtime insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mealtime insulin aspart
Study: 30487974
Drug: Bedtime insulin
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime insulin detemir
Study: 25537011
Drug: Tideglusib 1000
Normalized name: Tideglusib
DrugBank: Tideglusib (DB12129)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tideglusib 1000 mg QD
Study: 25537011
Drug: Tideglusib 1000
Normalized name: Tideglusib
DrugBank: Tideglusib (DB12129)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tideglusib 1000 mg QOD
Study: 25537011
Drug: Tideglusib 500
Normalized name: Tideglusib
DrugBank: Tideglusib (DB12129)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tideglusib 500 mg QD
Study: 23522973
Drug: Radionuclide therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radionuclide therapy (Samarium‐153 EDTMP), N=12
Study: 23522973
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no radionuclide therapy), N=12
Study: 20693354
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart administered 15 min before mealtime
Study: 12826500
Drug: Captopril (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (administered 8 hours and 1 hour before coronary angiography)
Study: 12826500
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no captopril treatment)
Study: 11196396
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg/day for 1 week, increased to 40 mg/day for the following weeks
Study: 11196396
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg/day plus local application of lidocaine ointment
Study: 11196396
Drug: Fluoxetine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine plus lidocaine ointment
Study: 8992100
Drug: Cefixime 8
Normalized name: cefixime 8 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime 8 mg/kg bodyweight once daily for 5 days
Study: 24755906
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg three times a day for 3 days)
Study: 20586522
Drug: Pregabalin (300,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (300, 450, and 600 mg daily)
Study: 18852414
Drug: IVT treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVT treatment followed by PDT
Study: 17058733
Drug: 2-liter electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-liter electrolyte lavage solution plus 20 mg of oral bisacodyl
Study: 7488484
Drug: vecuronium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: vecuronium 0.1 mg kg‐1
Study: 8739020
Drug: Intravenous quinaprilat
Normalized name: quinaprilat
DrugBank: Quinaprilat (DB14217)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous quinaprilat 0.5 mg
Study: 8739020
Drug: Intravenous quinaprilat
Normalized name: quinaprilat
DrugBank: Quinaprilat (DB14217)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous quinaprilat 1.0 mg and higher
Study: 10024837
Drug: Intravenous quinaprilat
Normalized name: quinaprilat
DrugBank: Quinaprilat (DB14217)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous quinaprilat
Study: 8739020
Drug: Intravenous quinaprilat
Normalized name: quinaprilat
DrugBank: Quinaprilat (DB14217)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous quinaprilat 2.5 mg
Study: 8739020
Drug: Intravenous quinaprilat
Normalized name: quinaprilat
DrugBank: Quinaprilat (DB14217)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous quinaprilat 10 mg
Study: 8739020
Drug: Oral quinapril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral quinapril 20 mg
Study: 8739020
Drug: Intravenous quinaprilat
Normalized name: quinaprilat
DrugBank: Quinaprilat (DB14217)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous quinaprilat 10 mg and oral quinapril 20 mg
Study: 6352533
Drug: 3% undecylenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% undecylenic acid and its zinc salt cream
Study: 30015785
Drug: Child‐ and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child‐ and Family‐focused Cognitive‐Behavioral Therapy (CFF‐CBT)
Study: 28112799
Drug: Oxymatrine (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymatrine (0.6 g per day for 8 weeks)
Study: 28112799
Drug: Acitretin (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acitretin (0.75 mg kg‐1 per day from week 0 to week 2 and 20‐30 mg per day from week 3 to week 8)
Study: 18398801
Drug: Augmentation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentation with atypical antipsychotics (AAP), particularly olanzapine; specific dosage and duration not mentioned.
Study: 18398801
Drug: Augmentation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentation with atypical antipsychotics (AAP); specific dosage and duration not mentioned.